Summary
Vertex Pharmaceuticals Incorporated reported strong financial performance in its 2020 10-K filing, with significant revenue growth driven by its cystic fibrosis (CF) medicines, particularly the triple combination therapy TRIKAFTA/KAFTRIO. The company's strategic focus on developing transformative medicines for serious diseases continues, with substantial investments in research and development across CF, Alpha-1 Antitrypsin (AAT) deficiency, APOL1-mediated kidney diseases, pain, and emerging areas like cell and genetic therapies for sickle cell disease, beta-thalassemia, and Type 1 Diabetes. Vertex is expanding its CF treatment reach by seeking label expansions for younger age groups and is actively developing genetic therapies for the remaining CF patient population not addressable by small molecule modulators. The company's robust pipeline, coupled with a strong cash position and ongoing share repurchase program, positions it for continued growth. Key risks include competitive pressures, reliance on a few key products, regulatory hurdles, and reimbursement challenges in international markets. However, the company's consistent revenue growth and pipeline advancements indicate a positive trajectory for investors.
Financial Highlights
52 data points| Revenue | $6.21B |
| Cost of Revenue | $736.30M |
| Gross Profit | $5.47B |
| R&D Expenses | $1.83B |
| SG&A Expenses | $770.50M |
| Operating Expenses | $3.35B |
| Operating Income | $2.86B |
| Interest Expense | $58.15M |
| Net Income | $2.71B |
| EPS (Basic) | $10.44 |
| EPS (Diluted) | $10.29 |
| Shares Outstanding (Basic) | 259.80M |
| Shares Outstanding (Diluted) | 263.40M |
Key Highlights
- 1Record revenue growth in 2020, primarily driven by strong performance of cystic fibrosis (CF) medicines, especially the triple combination therapy TRIKAFTA/KAFTRIO.
- 2Significant investment in research and development across multiple therapeutic areas, including CF, AAT deficiency, APOL1-mediated kidney diseases, pain, and cell/gene therapies.
- 3Advancement of multiple pipeline programs into clinical trials, including CTX001 (gene editing for sickle cell disease and beta-thalassemia) and VX-880 (cell therapy for Type 1 Diabetes).
- 4Expansion of TRIKAFTA/KAFTRIO eligibility to younger age groups and development of genetic therapies for the remaining 10% of CF patients not covered by current small molecule treatments.
- 5Strong liquidity position with over $6.6 billion in cash, cash equivalents, and marketable securities as of December 31, 2020.
- 6Continued share repurchase program, with approximately $424.9 million remaining authorized for repurchase.
- 7Commitment to scientific innovation and expanding therapeutic capabilities into cell and genetic therapies through acquisitions and collaborations.